Alloimmunization After Transfusion of RhD-incompatible Platelet Concentrates

摘要

An incidence of up to 19% of RhD-immunization after transfusion of RhD-incompatible platelet concentrates has been described previously. Additional studies did not find any alloimmunization in patients suffering from haematological malignancies . It is supposed that the immunosuppressive effect of their treatment may significantly reduce their ability for alloimmunization. Therefore, we compared transfused patients suffering from haematological, oncological and non-malignant diseases. The risk for sensitisation was 10% for haematological, 14% for oncological patients and 8% for patients with non-malignant diseases. With respect to improved long-term prognosis of patients with malignant diseases the administration of an intravenous RhD-prophy-laxis should be once more considered.